close
This ad will auto close in 10 seconds
Indian pharma companies' profiles better than global peers: Moody's

Indian pharma companies' profiles better than global peers: Moody's

The Indian pharmaceutical companies exhibit strong business profiles underpinned by good products and geographic diversity as compared to some global peers, American rating agency Moody`s said on Friday.

Drugs to become cheaper as panel recommends putting cap on trade margins

Drugs to become cheaper as panel recommends putting cap on trade margins

For drugs priced between Rs 20-50, the panel has proposal to cap the margin at 40 percent.

'Indian pharma industry capable of discovering new drugs'

'Indian pharma industry capable of discovering new drugs'

Indian pharma industry is capable of discovering at least a couple of new drugs in the next 10 years, Sun Pharmaceutical Industries founder and managing director Dilip Shanghvi said today

'Pharma exports may have grown 2.2% to $15.2 bn in FY15'

Indian pharma exports are estimated to have grown, but at a slower pace of 2.2 percent to about USD 15.2 billion during the financial year ended March 2015 against USD 14.9 billion in the previous fiscal, said a top official of Pharmexcil, an export promotion body, Monday.

Kumar calls for policy, regulation shift in Pharma sector

Calling for a shift in policy and regulation in pharma sector, government Tuesday stressed on the need for pharma industry to make quality medicines available to public at affordable rates.

Sun-Ranbaxy deal gets FIPB nod

The Sun Pharma-Ranbaxy transaction would create the country's largest pharmaceutical company.

Pharma industry needs to identify, retain talent: Experts

The domestic pharmaceutical industry, which has been growing at a steady pace, faces the challenge of identifying the right talent and retaining them for long-term, experts have said.

Cipla gains after April-June margins expand sequentially

Shares in drugmaker Cipla gain after April-June operating margins beat some estimates.

Pharma trade can help boost Indo-Pak ties: Icrier

Pharma sector, which has trade potential of USD 1.63 billion between India and Pakistan, can be an ideal area to improve bilateral relations, says a study by economic think-tank Icrier.

'Indian pharma cos face problems in US due to documentation'

Problems faced by Indian drug makers in the US are not related with quality but more due to documentation and data maintenance, a senior government official said Tuesday.

Make essential drugs affordable for all: Cipla

Amid US firms' allegations of patent norm violations against Indian pharma companies, leading domestic drug maker Cipla has said that "essential" medicines be made available to people at affordable rates and should not be sold under "monopoly".

FDI in pharma doubled during Apr-Dec

FDI in drugs and pharmaceuticals was USD 589 million in the April-December period of 2012-13, according to the latest data of the Department of Industrial Policy and Promotion.

GlaxoSmithKline raises India unit stake to 75% via open offer

UK-based GlaxoSmithKline Plc (GSK) Monday said it increased its stake in its Indian arm to 75 percent following the successful completion of a Rs 6,400 crore open offer.

GSK pays $1 billion to lift Indian unit stake to 75%

GlaxoSmithKline said on Monday it had paid 64 billion rupees to increase its stake in its Indian pharmaceuticals unit to 75 percent, as it banks on rising demand for medicines in emerging markets.

Govt retains 100% FDI in existing pharma units

Government Wednesday decided to retain the policy of allowing 100 percent foreign investment in the existing pharma firms, brushing aside concerns about non- availability of affordable drugs in view of MNCs takeovers.

Hiring grows by 24% in recession-proof pharma sector

Amid continuing business expansion, hiring in India's pharmaceutical sector grew an estimated 24 percent in the current financial year and job creation may continue in the near future.

Indian pharma draws more scrutiny as US exports rise

India's drugmakers, battered by a rash of US regulatory rebukes including a record fine for Ranbaxy Laboratories, face closer FDA scrutiny as the agency ramps up its presence in the country.

FDI policy in pharma set for major overhaul

The government is set to make major changes in the current FDI policy in the pharmaceuticals sector to protect domestic generic industry in the wake of increasing acquisitions of homegrown companies by foreign players.

US to hike fees for generic drugmakers; Indian firms to be hit

Many Indian drugmakers will soon have to bear higher costs for sale of products in American markets, as the US health regulator FDA is hiking the fees for generic drugmakers by up to 48 percent from October.

FIPB likely to defer FDI proposals in pharma sector

The Finance Ministry may defer 10 proposals for FDI in pharmaceutical sector that are listed to be taken up at the FIPB meeting Friday, as the government is yet to review foreign investment policy in existing Indian drug companies.